Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.36 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.34 |
| ▸ | UBE2N | P61088 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | TYMP | P19971 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 3/20 | 0.31 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CDKN1A | P38936 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | NT5E | P21589 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28280335 | 0.80 | BACE1 (0.32) | BACE1TYMPKIF11BACE2 | |
| SCHEMBL5150771 | 0.77 | NT5E (0.51) | ST6GAL1TYMPNT5E | |
| SCHEMBL30514382 | 0.76 | TYMP (0.42) | BACE1ST6GAL1MAPK14TYMP | |
| SCHEMBL10430325 | 0.76 | ST6GAL1 (0.31) | ST6GAL1 | |
| SCHEMBL28758788 | 0.75 | PDE4D (0.42) | BACE1ALDH1A1 | |
| SCHEMBL5859677 | 0.74 | — | — | |
| SCHEMBL6835021 | 0.73 | TYMP (0.39) | BACE1ST6GAL1TYMP | |
| SCHEMBL7175441 | 0.73 | TYMP (0.38) | ST6GAL1TYMP | |
| SCHEMBL4344762 | 0.73 | BACE1 (0.33) | BACE1KDM4EKIF11 | |
| SCHEMBL7813909 | 0.73 | EGFR (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070218490-A1 | NUCLEIC ACID MONOMERS WITH 2'-CHEMICAL MOIETIES | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2007-09-20 | — | — | US | disclosed |
| WO-2007106907-A2 | NUCLEIC ACID MONOMERS WITH 2'-CHEMICAL MOIETIES | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070218490-A1 | NUCLEIC ACID MONOMERS WITH 2'-CHEMICAL MOIETIES | POLRMT, RNGTT, POLM | BACE1 4732/4885ST6GAL1 2390/4885UBE2N 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.